168 related articles for article (PubMed ID: 21828952)
1. Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope.
Sato A; Maie K; Ohno Y; Yoshida T; Ito E; Tanabe Y; Aizawa Y
Int Heart J; 2011; 52(4):243-5. PubMed ID: 21828952
[TBL] [Abstract][Full Text] [Related]
2. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
Kuntzen C; Gülberg V; Gerbes AL
Gastroenterology; 2005 Jan; 128(1):164-8. PubMed ID: 15633133
[TBL] [Abstract][Full Text] [Related]
3. Bosentan therapy for portopulmonary hypertension.
Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
[TBL] [Abstract][Full Text] [Related]
4. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
Molnar C; Alber H; Colleselli D; Vogel W; Kähler CM
Wien Klin Wochenschr; 2004 Sep; 116(17-18):627-30. PubMed ID: 15515882
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of portopulmonary hypertension with bosentan: case report.
Stähler G; von Hunnius P
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
[TBL] [Abstract][Full Text] [Related]
6. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
Grander W; Eller P; Fuschelberger R; Tilg H
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():67-70. PubMed ID: 16919014
[TBL] [Abstract][Full Text] [Related]
7. Endothelin-receptor antagonist treatment of portopulmonary hypertension.
Hinterhuber L; Graziadei IW; Kähler CM; Jaschke W; Vogel W
Clin Gastroenterol Hepatol; 2004 Nov; 2(11):1039-42. PubMed ID: 15551258
[TBL] [Abstract][Full Text] [Related]
8. Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan.
Hino T; Hayashida A; Okahashi N; Wada N; Watanabe N; Obase K; Neishi Y; Kawamoto T; Okura H; Yoshida K
Intern Med; 2009; 48(8):597-600. PubMed ID: 19367055
[TBL] [Abstract][Full Text] [Related]
9. Bosentan improved syncope in a hemodialysis patient with pulmonary hypertension and mild aortic stenosis.
Yamanaka A; Tasaki H; Suzuki Y; Tanaka S; Yamashita K; Tamura M; Abe H; Otsuji Y
Int Heart J; 2006 Nov; 47(6):911-7. PubMed ID: 17268125
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
Sağ S; Yeşilbursa D; Güllülü S
Turk J Gastroenterol; 2014 Aug; 25(4):429-32. PubMed ID: 25254528
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
Halank M; Kolditz M; Miehlke S; Schiemanck S; Schmeisser A; Hoeffken G
Wien Med Wochenschr; 2005 Aug; 155(15-16):376-80. PubMed ID: 16160926
[TBL] [Abstract][Full Text] [Related]
12. Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
Muraoka H; Imamura T; Hatano M; Maki H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2015; 56(4):471-3. PubMed ID: 26084462
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
Shimizu M; Hashida Y; Ueno K; Yokoyama T; Nakayama Y; Saito T; Ohta K; Takehara K; Yachie A
Pediatr Cardiol; 2011 Oct; 32(7):1040-2. PubMed ID: 21789477
[TBL] [Abstract][Full Text] [Related]
14. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
Barth F; Gerber PJ; Reichen J; Dufour JF; Nicod LP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1117-9. PubMed ID: 16957519
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan.
Clift PF; Townend JN; Bramhall S; Isaac JL
Transplantation; 2004 Jun; 77(11):1774-5. PubMed ID: 15201683
[No Abstract] [Full Text] [Related]
16. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
[TBL] [Abstract][Full Text] [Related]
17. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension.
Halank M; Miehlke S; Hoeffken G; Schmeisser A; Schulze M; Strasser RH
Transplantation; 2004 Jun; 77(11):1775-6. PubMed ID: 15201684
[No Abstract] [Full Text] [Related]
18. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
[TBL] [Abstract][Full Text] [Related]
19. The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
Ashfaq M; Chinnakotla S; Rogers L; Ausloos K; Saadeh S; Klintmalm GB; Ramsay M; Davis GL
Am J Transplant; 2007 May; 7(5):1258-64. PubMed ID: 17286619
[TBL] [Abstract][Full Text] [Related]
20. Current status of bosentan for treatment of pulmonary hypertension.
Raja SG; Dreyfus GD
Ann Card Anaesth; 2008; 11(1):6-14. PubMed ID: 18182753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
